MACROGENICS, INC. (NASDAQ:MGNX) Files An 8-K Other Events

On October 22, 2019, MacroGenics, Inc. issued a press release announcing topline results from the second pre-specified interim overall survival analysis for its Phase 3 SOPHIA study of margetuximab. SOPHIA is a randomized, controlled, multi-center study that compares margetuximab plus chemotherapy to trastuzumab plus chemotherapy in subjects with metastatic breast cancer.

A copy of the press release (the “Press Release") is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release, dated October 22, 2019.

MACROGENICS INC Exhibit
EX-99.1 2 exhibit99-1sophiaos.htm EX-99.1 DocumentExhbit 99.1MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast CancerROCKVILLE,…
To view the full exhibit click here

About MACROGENICS, INC. (NASDAQ:MGNX)

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.